UKF-26954-86042
4 vaccinations
5 coded responses
45 check-ins
5 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 641 / MO
- Registered
- 2020-12-30
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Registered dependents
QCP-15436-19202
Child or adolescent in my care · Male · 2022-07-08
EGA-83676-15011
Child or adolescent in my care · Female · 2022-07-08
L2Y-79524-38819
Child or adolescent in my care · Male · 2022-10-03
Timeline
-
2020-12-30
Registered in v-safe
-
2020-12-30
Dose 1 — Pfizer-BioNTech
-
2020-12-30
Survey response — day 0, dose 1MedDRA: Hyperhidrosis — Feeling: Good · HeadacheFree text: SweatingMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-03
- 2021-01-04
- 2021-01-06
- 2021-01-13
-
2021-01-20
Dose 2 — Pfizer-BioNTech
-
2021-01-20
Survey response — day 0, dose 2MedDRA: Dysgeusia — Feeling: Good · Site: Pain · HeadacheFree text: Metallic taste in mouthMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-21
- 2021-01-22
- 2021-01-23
-
2021-01-24
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Headache, Fatigue or tiredness, Nausea, DiarrheaAdult check-in
- 2021-01-25
-
2021-01-26
Health check-in — days 1–6 daily, dose 2Feeling: Good · Headache, Fatigue or tirednessAdult check-in
- 2021-01-27
- 2021-02-03
- 2021-02-10
- 2021-02-19
- 2021-02-24
- 2021-03-03
- 2021-04-21
- 2021-07-21
-
2021-10-26
Dose 3 — Pfizer-BioNTech
- 2021-10-26
-
2021-10-27
Survey response — days 1–6 daily, dose 3MedDRA: Flushing — Feeling: Good · Site: PainFree text: Facial flushingMedDRA releases: 2024-11 · check-in free text available
- 2021-10-28
- 2021-10-29
- 2021-10-30
-
2021-11-01
Health check-in — days 1–6 daily, dose 3Feeling: Good · Headache, Fatigue or tirednessAdult check-in
- 2021-11-02
- 2021-11-09
- 2021-11-16
- 2021-11-23
- 2021-11-30
- 2021-12-07
- 2022-01-25
-
2022-04-26
Survey response — 6 months, dose 3MedDRA: Pain, Respiratory symptom — Feeling: Good · Be unable to do your normal daily activitiesFree text: Upper respiratory symptoms and body achesMedDRA releases: 2024-11 · check-in free text available
-
2022-09-30
Dose 4 — Pfizer-BioNTech
- 2022-10-03
- 2022-10-05
- 2022-10-06
- 2022-10-07
- 2022-10-14
- 2022-11-06
-
2022-12-30
Survey response — 3 months, dose 4MedDRA: Upper respiratory tract infection — Feeling: GoodFree text: 2 upper respiratory infectionsMedDRA releases: 2024-11 · check-in free text available
- 2023-03-31
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-30 | Pfizer-BioNTech | |
| 2 | 2021-01-20 | Pfizer-BioNTech | |
| 3 | 2021-10-26 | Pfizer-BioNTech | No |
| 4 | 2022-09-30 | Pfizer-BioNTech | No |
Free text
Release 1 — day 0, dose 1
Systemic reaction (other): Sweating
Release 2 — day 0, dose 2
Systemic reaction (other): Metallic taste in mouth
Release 10 — days 1–6 daily, dose 3
Systemic reaction (other): Facial flushing
Release 11 — 6 months, dose 3
Symptoms: Upper respiratory symptoms and body aches
Release 12 — 3 months, dose 4
Symptoms: 2 upper respiratory infections
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Pain | · | · | ✓ |
| SD | Respiratory symptom | · | · | ✓ |
| SD | Upper respiratory tract infection | · | · | ✓ |
| SRO | Dysgeusia | ✓ | ✓ | ✓ |
| SRO | Flushing | · | · | ✓ |
| SRO | Hyperhidrosis | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release